Norepinephrine
Levophed, Norepinephrine, Ravocaine Novocain W/, Ravocaine Novocain W/ Levophed (norepinephrine) is a small molecule pharmaceutical. Norepinephrine was first approved as Ravocaine and novocain w/ neo-cobefrin on 1982-01-01. It is used to treat hypotension and shock in the USA. The pharmaceutical is active against alpha-2B adrenergic receptor and alpha-2C adrenergic receptor. In addition, it is known to target beta-3 adrenergic receptor, alpha-1A adrenergic receptor, beta-2 adrenergic receptor, beta-1 adrenergic receptor, D(1A) dopamine receptor, alpha-1B adrenergic receptor, D(1B) dopamine receptor, alpha-2A adrenergic receptor, and alpha-1D adrenergic receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Levophed, Norepinephrine (discontinued: Norepinephrine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Norepinephrine bitartrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE | Baxter | N-214313 RX | 2021-01-15 | 3 products, RLD, RS |
| LEVOPHED | Hospira | N-007513 RX | 1982-01-01 | 1 products, RLD, RS |
| NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE | InfoRLife | N-215700 RX | 2022-09-15 | 3 products, RLD, RS |
| NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE | Long Grove Pharmaceuticals | N-214628 RX | 2022-10-06 | 3 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| levophed | New Drug Application | 2024-08-02 |
| levophed(r) norepinephrine bitartrate | New Drug Application | 2021-02-05 |
| norepinephr bitart | ANDA | 2024-03-13 |
| norepinephrine | New Drug Application | 2024-02-12 |
| norepinephrine bitartrate | ANDA | 2024-11-01 |
| norepinephrine bitartrate in sodium chloride | New Drug Application | 2023-07-31 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hypotension | EFO_0005251 | D007022 | I95 |
| shock | — | D012769 | R57.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Norepinephrine Bitartrate, Norepinephrine Bitartrate In 0.9% Sodium Chloride, Inforlife | |||
| 10888534 | 2039-04-26 | DP | |
| Norepinephrine Bitartrate, Norepinephrine Bitartrate In 0.9% Sodium Chloride, Long Grove Pharms | |||
| 10159657 | 2038-01-30 | DP | |
| 10226436 | 2038-01-30 | DP | U-3461 |
| 10420735 | 2038-01-30 | DP | U-3461 |
| 10568850 | 2038-01-30 | DP | |
| 11413259 | 2038-01-30 | DP | U-3461 |
| 11602508 | 2038-01-30 | DP | |
HCPCS
No data
Clinical
Clinical Trials
1302 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 17 | 43 | 100 | 104 | 46 | 300 |
| Depression | D003863 | — | F33.9 | 9 | 42 | 95 | 101 | 50 | 287 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 16 | 29 | 80 | 74 | 33 | 225 |
| Hypotension | D007022 | EFO_0005251 | I95 | 3 | 5 | 14 | 31 | 63 | 114 |
| Shock | D012769 | — | R57.1 | 1 | 17 | 25 | 22 | 54 | 110 |
| Septic shock | D012772 | — | A48.3 | 1 | 16 | 24 | 14 | 44 | 91 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | 4 | 9 | 20 | 12 | 9 | 50 |
| Myofascial pain syndromes | D009209 | EFO_1001054 | — | 3 | 8 | 19 | 12 | 8 | 46 |
| Healthy volunteers/patients | — | — | — | 23 | — | 1 | 4 | 9 | 37 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | 3 | 14 | 10 | 9 | 35 |
Show 183 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhage | D006470 | MP_0001914 | R58 | — | 1 | 1 | — | 8 | 10 |
| Ischemic stroke | D000083242 | — | — | 1 | 2 | 1 | — | 5 | 9 |
| Neoplasms | D009369 | — | C80 | 2 | 4 | 2 | — | 2 | 8 |
| Cocaine-related disorders | D019970 | — | F14 | 1 | 6 | 1 | — | — | 8 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | 3 | — | 3 | 7 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | 1 | 2 | 1 | — | 4 | 7 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | 1 | 1 | — | 5 | 7 |
| Pure autonomic failure | D054970 | — | — | — | 1 | 3 | — | 2 | 6 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | 2 | 4 | 1 | — | 1 | 6 |
| Cardiac surgical procedures | D006348 | — | — | — | — | 2 | — | 4 | 6 |
Show 60 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | 1 | 2 | — | — | 5 | 7 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 4 | 1 | — | — | 2 | 7 |
| Primary dysautonomias | D054969 | — | — | 1 | 2 | — | — | 4 | 6 |
| Coronary artery disease | D003324 | — | I25.1 | — | 1 | — | — | 4 | 5 |
| Pheochromocytoma | D010673 | — | — | 1 | 1 | — | — | 2 | 4 |
| Shy-drager syndrome | D012791 | EFO_1001050 | — | 1 | 1 | — | — | 2 | 3 |
| Multiple system atrophy | D019578 | — | — | 1 | 1 | — | — | 2 | 3 |
| Hypoglycemia | D007003 | HP_0001943 | E16.2 | 1 | 1 | — | — | 2 | 3 |
| Acute liver failure | D017114 | HP_0004448 | — | — | 1 | — | — | 2 | 3 |
| Liver transplantation | D016031 | EFO_0010682 | — | 1 | 1 | — | — | 2 | 3 |
Show 40 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 3 | — | — | — | 4 | 7 |
| Amphetamine-related disorders | D019969 | EFO_0004701 | F15 | 4 | — | — | — | 1 | 5 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | — | — | 4 | 5 |
| Therapeutic equivalency | D013810 | — | — | 2 | — | — | — | 1 | 3 |
| Inflammation | D007249 | MP_0001845 | — | 1 | — | — | — | 1 | 2 |
| Hyperalgesia | D006930 | — | — | 2 | — | — | — | — | 2 |
| Heart disease risk factors | D000082742 | — | — | 2 | — | — | — | — | 2 |
| Blood circulation | D001775 | — | — | 1 | — | — | — | 1 | 2 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | — | — | — | — | 1 |
| Pulmonary arterial hypertension | D000081029 | — | — | 1 | — | — | — | — | 1 |
Show 10 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carotid endarterectomy | D016894 | — | — | — | — | — | — | 4 | 4 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | — | 3 | 3 |
| Intraoperative complications | D007431 | — | — | — | — | — | — | 3 | 3 |
| Obstetrical anesthesia | D000773 | — | — | — | — | — | — | 3 | 3 |
| Hemorrhagic shock | D012771 | — | — | — | — | — | — | 3 | 3 |
| Heart arrest | D006323 | EFO_0009492 | I46 | — | — | — | — | 3 | 3 |
| Cardiac output | D002302 | — | — | — | — | — | — | 3 | 3 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | — | 3 | 3 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | — | — | 2 | 2 |
| Atrophy | D001284 | — | — | — | — | — | — | 2 | 2 |
Show 152 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Norepinephrine |
| INN | norepinephrine |
| Description | (R)-noradrenaline is the R-enantiomer of noradrenaline. It has a role as a vasoconstrictor agent, an alpha-adrenergic agonist, a sympathomimetic agent, a mouse metabolite and a neurotransmitter. It is a conjugate base of a (R)-noradrenaline(1+). It is an enantiomer of a (S)-noradrenaline. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NC[C@H](O)c1ccc(O)c(O)c1 |
Identifiers
| PDB | — |
| CAS-ID | 51-41-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1437 |
| ChEBI ID | 18357 |
| PubChem CID | 439260 |
| DrugBank | DB00368 |
| UNII ID | X4W3ENH1CV (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
ADRA1D
ADRA1D
ADRB1
ADRB1
Organism
Homo sapiens
Gene name
ADRA1D
Gene synonyms
ADRA1A
NCBI Gene ID
Protein name
alpha-1D adrenergic receptor
Protein synonyms
adrenergic, alpha -1D-, receptor, adrenergic, alpha-1A-, receptor, Alpha-1A adrenergic receptor, Alpha-1D adrenoceptor, Alpha-1D adrenoreceptor, Alpha-adrenergic receptor 1a
Uniprot ID
Mouse ortholog
Adra1d (11550)
alpha-1D adrenergic receptor (P97714)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 66,784 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,267 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use